On August 28, 2023 Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, reported that Fierce Biotech has recognized the company as one of its "Fierce 15" for 2023 (Press release, Palleon Pharmaceuticals, AUG 28, 2023, View Source [SID1234634733]). This annual report features the most innovative and promising biotechnology companies in the industry.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"It is an honor to be named to the Fierce 15 and to be recognized for our work pioneering the transformational field of glyco-immunology," said Jim Broderick, M.D., Chief Executive Officer and Founder of Palleon. "As we continue to advance our therapies in the clinic, this recognition provides validation of the strength of our team, our technologies, and our strategy to bring much-needed new therapeutic options to patients across multiple disease areas."
Palleon was co-founded by Dr. Carolyn Bertozzi, recipient of the 2022 Nobel Prize in Chemistry for the invention of bioorthogonal chemistry, a technology which enabled the company’s foundational science. In April 2023, Palleon announced Phase 1 results from the GLIMMER-01 trial to evaluate its lead candidate in oncology, E-602 as a monotherapy, demonstrating proof of mechanism, including dose dependent desialylation and dose dependent immune system activation. Additionally, E-602 was found to be well tolerated across the entire dose range evaluated with no dose limiting toxicities.
For the past 21 years, the Fierce Life Sciences team has assessed hundreds of companies for inclusion in the ‘Fierce 15’ special report. To curate this list, Fierce considers a diverse range of factors, including the robustness of technology, partnerships, venture support, and competitive positioning within the market. This special report celebrates innovation and creativity in the face of intense competition.